Frontlight ResearchEarly access
Taking people in United StatesPhase 2
Pregnenolone for the Treatment of Alcohol Use Disorder
Key facts
- Who runs it
- Yale University
- Where
- New Haven, United StatesSee the site
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 150 people, planned
- Started
- 8 Jan 2024
- Expected to end
- 31 Jul 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Pregnenolone
- Placebo
- Record updated
- 2 February 2026
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Male and females, aged 18-70 years
- Regular weekly use of alcohol at least 3X weekly or more at treatment entry
- Must meet current DSM-5 criteria for moderate to severe Alcohol Use Disorders (AUDs) using SCID-I for DSM-5
- No health conditions that would impact trial participation as verified by screening and physical examination and absence of any of the exclusion criterions outlined below
- Able to read English and complete study evaluations
- Able to provide informed written and verbal consent
Who cannot take part
- Regular use of anticonvulsants, sedatives or hypnotics, oral prescription analgesics (other than non-steroidal anti-inflammatory drugs), topiramate, baclofen
- Regular use of steroidal supplements and steroid medications interacting with study medications based on clinical judgement of study physician (excluding hormonal contraceptives in women)
- Meet current criteria for moderate to severe substance use disorders from use of any other psychoactive substance, excluding nicotine and cannabis use disorder
- Significant underlying medical conditions such as cerebral, renal, thyroid or cardiac pathology which in the opinion of study physician would preclude patient from fully cooperating or be of potential harm during the course of the study, but stable, prescribed anti-hypertensives. cardiovascular and diabetes medications will be allowed after review by study physician
- Any psychotic disorder or current Axis I psychiatric disorders requiring specific acute attention, including need for psychiatric medications, but stable, prescribed antidepressants and anti-anxiety medication to treat co-occurring psychiatric disorders will be allowed
- Current use of opioids
- Psychotic or otherwise severely psychiatrically disabled (i.e., suicidal, homicidal, current mania)
- Women who are pregnant, nursing or refuse to use a reliable form of birth control (as assessed by urine pregnancy tests during initial medical evaluation, and assessed every two weeks during the course of the study)
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
This trial is currently available in United States.
- The Yale Stress Center: Yale UniversityNew Haven, United StatesContact: Rachel Hart, MSTaking people
About the trial
What the trial wants to find out
This Phase 2 randomized cotrolled trial (RCT) will assess the safety and efficacy of pregnenolone (PREG; 300 mg/day, b.i.d dosing) vs. placebo (PBO) over a 12 week treatment period, and at 1-month post-treatment follow-up in individuals with Alcohol Use Disorder (AUD).
The 2 groups in the trial
- patients receiving 300mg PREGExisting treatment, for comparison
Patients randomly assigned to receive 300mg of pregnenolone (PREG) daily.
Treatment: Pregnenolone
- placeboPlacebo, for comparison
Patients randomly assigned to receive a placebo daily.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT05781009, who can take part
- Record updated
- 2 February 2026